Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Johnson Research & Development (United States) | Researchclopedia

Back to institutions

Johnson Research & Development (United States)

Atlanta, Georgiacompany

193

Works

15,353

Citations

72

h-index

Top Research Topics

Helminth infection and control Microbial infections and disease research Pharmacogenetics and Drug Metabolism

Top Researchers

John Nemunaitis Gradalis (United States)

807 works35,702 citationsh-index: 92

Recent Research

Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study

Christine Pinter,Michael E Thase,et al.

20260 citations

Ruminant Nutrition and Digestive Physiology

Inflammatory Bowel Disease

Reproductive Physiology in Livestock

Antibiotics Pharmacokinetics and Efficacy

Mast cells and histamine

Plant and fungal interactions

Pharmacological Effects and Assays

Psoriasis: Treatment and Pathogenesis

Treatment of Major Depression

Karen Bush George Washington University

311 works30,569 citationsh-index: 74

126 works29,212 citationsh-index: 46

David I. Quinn AbbVie (United States)

829 works28,026 citationsh-index: 77

Thomas Steckler Johnson & Johnson (United States)

2,866 works27,519 citationsh-index: 54

Thomas E. Johnson Texas A&M University – Texarkana

383 works22,105 citationsh-index: 74

Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study

Anna Minchom,Byoung Chul Cho,et al.

20260 citations

P1043 Unsupervised machine learning to identify distinct CDAI-based response patterns to guselkumab in participants with Crohn’s disease: Post hoc analysis of the pooled GRAVITI and GALAXI 2/3 studies

S W Schreiber,G D’Haens,et al.

20260 citations

DOP103 Intravenous and subcutaneous guselkumab induction are similarly efficacious in patients with ulcerative colitis across weight quartile and BMI subgroups: Week 12 results from the phase 3 QUASAR and ASTRO studies

Andrés Yarur,Parakkal Deepak,et al.

20260 citations

DOP001 Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies

S Danese,T Hisamatsu,et al.

20260 citations

P1110 Efficacy of intravenous and subcutaneous guselkumab induction by weight and body mass index in patients with Crohn’s disease: Results from the phase 3 GALAXI and GRAVITI studies

Parakkal Deepak,Andrés Yarur,et al.

20260 citations